We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
- Authors
Gentschev, Ivaylo; Szalay, Aladar A.; Adelfinger, Marion; Langbein-Laugwitz, Johanna; Bessler, Simon; Cecil, Alexander; Frentzen, Alexa
- Abstract
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3), prostate carcinoma (CT1258), and soft tissue sarcoma (STSA-1). The GLV-5b451 virus-mediated production of GLAF-2 antibody was observed in all four cancer cell lines. In addition, this antibody specifically recognized canine VEGF. Finally, in canine soft tissue sarcoma (CSTS) xenografted mice, a single systemic administration of GLV-5b451 was found to be safe and led to anti-tumor effects resulting in the significant reduction and substantial long-term inhibition of tumor growth. A CD31-based immuno-staining showed significantly decreased neo-angiogenesis in GLV-5b451-treated tumors compared to the controls. In summary, these findings indicate that GLV-5b451 has potential for use as a therapeutic agent in the treatment of CSTS.
- Subjects
CANCER in dogs; VACCINIA; ANTIBODY formation; NEOVASCULARIZATION; CELL culture; SARCOMA; SOFT tissue tumors; CANCER treatment
- Publication
Viruses (1999-4915), 2015, Vol 7, Issue 7, p4075
- ISSN
1999-4915
- Publication type
Article
- DOI
10.3390/v7072811